XML 63 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
License agreements                      
Research and development expense             $ 269,612 $ 143,184 $ 879,423 $ 420,276  
Unrealized gain (loss) on long term investments             23,045 24,301 (2,343) 20,497  
Long term investment             169,020   $ 169,020   $ 31,987 [1]
Agenus                      
License agreements                      
Number of program targets | item       3   4          
Royalty payments on future global net sales (as a percent)                 15.00%    
Period of notice for termination of license agreement     12 months                
Agenus | Development, Regulatory and Commercialization Milestones                      
License agreements                      
Additional milestone payments under the license agreement     $ 510,000                
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                      
License agreements                      
Royalty payments on future global net sales (as a percent)                 6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                      
License agreements                      
Royalty payments on future global net sales (as a percent)                 12.00%    
Agenus | Development Milestones                      
License agreements                      
Upfront payment under license agreement                 $ 20,000    
Agenus                      
License agreements                      
Research and development expense             29,700 3,900 48,600 12,000  
Shares owned following stock purchase (as a percent) 11.00%       9.00%            
Ownership percentage (as a percent) 18.00%                    
Unrealized gain (loss) on long term investments             10,200 $ 24,300 (6,800) $ 20,500  
Long term investment             78,300   78,300   32,000
Total revenues             4,200   31,200    
Net income (loss)             (31,700)   (48,800)    
Agenus | Accrued and other liabilities                      
License agreements                      
Accrued and other liabilities             $ 3,500   3,500   $ 11,400
Agenus | Stock purchase agreement                      
License agreements                      
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                  
Purchase price of common stock   $ 60,000                  
Per share price | $ / shares $ 4.40 $ 6.00                  
Discount for lack of marketability $ 4,500                    
Fair value of shares on the issuance date 39,500                    
Total consideration paid 60,000                    
Research and development expense                 $ 20,500    
Long term investment $ 39,500                    
[1] The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date.